[Metabolic impact of androgen deprivation therapy for prostate cancer].

Abstract : Because of the low mortality rates associated with prostate cancer, treatments long-term adverse effects constitute an important parameter in the management of patients. In particular, androgen deprivation has been shown to be linked to several metabolic disorders which are already frequent in men after age 60, such as weight and fat gain, insulin resistance likely to evolve into diabetes, and dyslipidemia. So far no consensus guidelines have been published regarding the screening and treatment of metabolic disorders in men with prostate cancer. It is essential to detect and manage these metabolic disorders, all the more so as they seem to be associated with an increased aggressiveness of prostate cancer. Here we report the development of a new questionnaire, which might contribute to the systematic management, and potentially the screening and treatment or the prevention of these metabolic disorders in patients with prostate cancer. In accordance with recent reviews and on the basis of experience, our French board of experts also recommends systematic screening and selective treatment for diabetes, regular follow-up of fasting glucose rates, lipid profile and blood pressure in all patients under long-term androgen deprivation treatment, as well as lifestyle changes (practice of exercise, nutritional habits).
Type de document :
Article dans une revue
Progrès en Urologie, Elsevier Masson, 2012, 22 Suppl 2, pp.S39-47. 〈10.1016/S1166-7087(12)70035-0〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00820957
Contributeur : Philippe Saas <>
Soumis le : mardi 7 mai 2013 - 09:44:59
Dernière modification le : vendredi 9 février 2018 - 16:54:02

Identifiants

Collections

Citation

Emmanuel Andrès, Pascal Eschwege, Hervé Lang, Jean-Luc Moreau, Didier Peiffert, et al.. [Metabolic impact of androgen deprivation therapy for prostate cancer].. Progrès en Urologie, Elsevier Masson, 2012, 22 Suppl 2, pp.S39-47. 〈10.1016/S1166-7087(12)70035-0〉. 〈inserm-00820957〉

Partager

Métriques

Consultations de la notice

142